Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Scleroderma is a complex connective tissue disease involving three interconnected pathophysiological axes: vascular hyperactivity and remodelling, immune system dysfunction and over-activation of fibroblasts at the origin of the fibrosis process in the skin and organs. Given that this pathology occurs preferentially in mature subjects, it is possible to suggest a potential inductive role for senescent fibroblasts, which would be responsible for activating and/or maintaining the immune response and systemic inflammation. Our hypothesis is that fibroblasts play a predominant role in the genesis and maintenance of this pathology.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| scleroderma | People with systemic scleroderma |
| |
| Control | People undergoing plastic, cosmetic and reconstructive surgery |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Skin samples | Procedure |
|
| Measure | Description | Time Frame |
|---|---|---|
| genes involved in the various cell activation and signalling pathways | number and type of genes involved in different cell activation and signalling pathways, including senescence, which will be differentially expressed in fibroblasts from the skin of control participants and those from the skin of subjects with SSc. | through study completion, an average of 12 months |
Not provided
Not provided
Inclusion Criteria:
FOR PATIENTS WITH SCLERODERMA :
FOR CONTROL PARTICIPANTS :
Exclusion Criteria:
FOR PATIENTS WITH SCLERODERMA :
FOR CONTROLLED PARTICIPANTS :
Not provided
Not provided
Not provided
Eligible participants (patients and control participants) will be identified during their usual follow-up consultation.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Bernard BONNOTTE | Contact | 03.80.29.34.32 | +33 | Bernard.bonnotte@chu-dijon.fr |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU Dijon Bourgogne | Recruiting | Dijon | 21000 | France |
Not provided
| ID | Term |
|---|---|
| D045743 | Scleroderma, Diffuse |
| ID | Term |
|---|---|
| D012595 | Scleroderma, Systemic |
| D003240 | Connective Tissue Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D012871 | Skin Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| Analysis of fibroblasts | Other | Analysis of samples by RNA sequencing |
|